Edward Wolin
Overview
Explore the profile of Edward Wolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cengiz T, Kulkarni R, Corbett V, Ghesani N, Wolin E, Ghesani M
Front Oncol
. 2025 Jan;
14():1432758.
PMID: 39845312
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive...
2.
Rustgi S, Oh A, Yang J, Kang D, Wolin E, Kong C, et al.
BMC Cancer
. 2021 May;
21(1):597.
PMID: 34030646
Background & Aims: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous neoplasms. Although some have a relatively benign and indolent natural history, others can be aggressive and ultimately fatal. Somatostatin analogues (SSAs)...
3.
Kessel E, Naparst M, Alpert N, Diaz K, Ahn E, Wolin E, et al.
Pancreas
. 2020 Dec;
50(1):29-36.
PMID: 33370020
Objectives: The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Methods: Using the Surveillance, Epidemiology, and End Results...
4.
Khetan P, Oyewole F, Wolin E, Kim M, Divino C
Pancreas
. 2020 Apr;
49(4):509-513.
PMID: 32224719
Objectives: Neuroendocrine tumors represent approximately 40% of primary small bowel malignancies. However, factors predictive of progression after multimodal surgical therapy have not been well described. We evaluated the characteristics of...
5.
Strosberg J, Kunz P, Hendifar A, Yao J, Bushnell D, Kulke M, et al.
Eur J Nucl Med Mol Imaging
. 2020 Mar;
47(10):2372-2382.
PMID: 32123969
Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial,...
6.
Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, et al.
PLoS One
. 2019 Sep;
14(9):e0221994.
PMID: 31527867
Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially...
7.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al.
J Clin Oncol
. 2018 Jun;
36(25):2578-2584.
PMID: 29878866
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of Lu-Dotatate treatment on time to deterioration in health-related QoL. Methods The...
8.
Yu R, Wolin E, Fan X
World J Oncol
. 2017 Nov;
1(5):204-207.
PMID: 29147207
We report a 50-year-old woman whose atypical lung carcinoid presented as a single subcutaneous nodule. Biopsy of the nodule revealed neuroendocrine carcinoma likely from the lungs. Imaging studies revealed masses...
9.
Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E, et al.
Cancer Sci
. 2017 Oct;
109(1):174-181.
PMID: 29055056
In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal...
10.
Pavel M, Singh S, Strosberg J, Bubuteishvili-Pacaud L, Degtyarev E, Neary M, et al.
Lancet Oncol
. 2017 Aug;
18(10):1411-1422.
PMID: 28838862
Background: In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report...